NCT00725374View on ClinicalTrials.gov

A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

December 15, 2002

Primary Completion Date

April 15, 2005

Study Completion Date

April 15, 2005

Conditions
Breast Cancer
Interventions
DRUG

tibolone

one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).

DRUG

placebo

Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00725374 - A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469) | Biotech Hunter | Biotech Hunter